Chao Family Comprehensive Cancer Center

University of California, Irvine

Orange, CA

Sorting 7 by

Accepting patients

MajesTEC-9

Phase 3 Clinical Trial Comparing a Study Medication Alone Versus Pomalidomide, Bortezomib, Dexamethasone or Carfilzomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
  • Bispecific Antibody
  • BCMA
  • Randomization
  • Phase 3

Not currently accepting

Iberdomide vs. Observation Post Ide-Cel CAR-T

Randomized Phase 2 Study of Iberdomide Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in Multiple Myeloma Patients
  • CELMoD
  • Maintenance
  • Randomization
  • Phase 2

Not yet accepting

IGI 10% (TAK-339)

A Multicenter, Randomized, Controlled, Open-label, Group-Sequential, Phase 3 Study to Investigate the Efficacy, Safety, and Tolerability of Intravenous Gammagard Liquid (Immune Globulin Infusion, 10%) for Primary Infection Prophylaxis Compared With Secondary Infection Prophylaxis in Adult Subjects With Multiple Myeloma Receiving B-Cell Maturation AntigenxCD3-Directed Bispecific Antibody Therapy
  • Randomization
  • Phase 3

Not yet accepting

MagnetisMM-15

Elranatamab Post Trial Access: An Open-Label, Single-Arm Study For Participants with Multiple Myeloma Continuing From Pfizer-Sponsored Elranatamab Clinical Studies
  • Bispecific Antibody
  • BCMA
  • CD3
  • Phase 4

Accepting patients

Sonrotoclax (BGB-11417)

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
  • BCL-2 Inhibitor
  • Phase 1/2
  • Has results

Accepting patients

AZD0305

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/​Refractory Multiple Myeloma
  • Antibody Drug Conjugate (ADC)
  • GPRC5D
  • Phase 1/2

Accepting patients

Dara-SVD vs. Dara-RVD

A Randomized Phase 2 Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Diagnosed Multiple Myeloma
  • SINE
  • Quadruplet Therapy
  • Phase 2